The Abbott Vascular Bifurcation Program Transitioning Pathfinder to the Xience S.B.A. Platform

European Bifurcation Club 2011, EBC 2011 – Lisbon, Portugal

The Abbott Vascular Bifurcation Program Transitioning Pathfinder to the Xience S.B.A. Platform

Author: David G. Rizik, MD, Scottsdale Heart Group at Scottsdale Healthcare Hospitals, USA

• There is no single, clear-cut regulatory pathway which ensures device approval.
• SB devices (Capella, Tryton) require different randomized trial design and comparator arms than other devices (Xience SBA, Boston Scientific Petal etc…)
• Where there is MB disease present, emphasis must remain on achieving durable main branch patency.
• Greatest emphasis: SIMPLICITY, SIMPLICITY, SIMPLICITY!!!!!!
• Devices need to be developed which can be applied broadly: i.e. to a heterogeneous pool of bifurcations including (and especially) LM disease.
• Until recently, the psychology of treating bifurcation lesions has been focused on the provisional SB methodology as a “preferred” treatment strategy.However, with newer data now being published which confirms the merit of an upfront 2-stent strategy, it seems reasonable that those devices providing the greatest versatility are likely to enjoy the greatest adoption (i.e. a dedicated devices would be applicable to 1-stent and 2-stent strategies, Provisional SB stenting, and even a simple SB preservation technique)

Download here